IDH2 and glioblastoma: In a recent study about Ki-67 index use as a biomarker for survival in IDH-wild-type GBM patients treated with radiochemotherapy, Dumke et al. showed that a Ki-67 index ≤ 20% can be an independent factor that predicts and correlates with longer survival rates [144].